Stem definition | Drug id | CAS RN |
---|---|---|
1747 | 532-03-6 |
Dose | Unit | Route |
---|---|---|
3 | g | O |
3 | g | P |
None
Date | Agency | Company | Orphan |
---|---|---|---|
July 16, 1957 | FDA | AUXILIUM PHARMS LLC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Completed suicide | 77.23 | 12.56 | 158 | 18485 | 131731 | 50454750 |
Necrosis ischaemic | 64.68 | 12.56 | 20 | 18623 | 779 | 50585702 |
Pneumonia streptococcal | 54.24 | 12.56 | 21 | 18622 | 1610 | 50584871 |
Beta haemolytic streptococcal infection | 48.48 | 12.56 | 20 | 18623 | 1810 | 50584671 |
Acquired haemophilia | 46.31 | 12.56 | 16 | 18627 | 887 | 50585594 |
Gallbladder polyp | 41.78 | 12.56 | 14 | 18629 | 707 | 50585774 |
Multiple drug therapy | 37.62 | 12.56 | 17 | 18626 | 1920 | 50584561 |
Maternal exposure during pregnancy | 37.03 | 12.56 | 7 | 18636 | 159771 | 50426710 |
Treatment failure | 36.61 | 12.56 | 4 | 18639 | 137633 | 50448848 |
Diabetes mellitus inadequate control | 35.19 | 12.56 | 33 | 18610 | 13112 | 50573369 |
Muscle spasms | 33.42 | 12.56 | 112 | 18531 | 125441 | 50461040 |
Systemic lupus erythematosus | 32.93 | 12.56 | 6 | 18637 | 140616 | 50445865 |
Drug intolerance | 32.91 | 12.56 | 20 | 18623 | 219084 | 50367397 |
Infusion related reaction | 32.43 | 12.56 | 11 | 18632 | 169546 | 50416935 |
Migraine | 29.43 | 12.56 | 77 | 18566 | 75203 | 50511278 |
Drug hypersensitivity | 29.28 | 12.56 | 175 | 18468 | 250835 | 50335646 |
Spinal operation | 27.70 | 12.56 | 21 | 18622 | 6239 | 50580242 |
Glossodynia | 26.90 | 12.56 | 5 | 18638 | 115564 | 50470917 |
Anxiety | 26.90 | 12.56 | 133 | 18510 | 177473 | 50409008 |
Amnesia | 26.32 | 12.56 | 52 | 18591 | 42208 | 50544273 |
Depression | 25.85 | 12.56 | 125 | 18518 | 165298 | 50421183 |
Exposure via skin contact | 25.02 | 12.56 | 7 | 18636 | 191 | 50586290 |
Fall | 24.73 | 12.56 | 209 | 18434 | 334723 | 50251758 |
Surgery | 22.33 | 12.56 | 40 | 18603 | 30165 | 50556316 |
Intervertebral disc protrusion | 21.90 | 12.56 | 32 | 18611 | 20361 | 50566120 |
Off label use | 20.83 | 12.56 | 97 | 18546 | 474329 | 50112152 |
Exercise tolerance decreased | 20.80 | 12.56 | 16 | 18627 | 4858 | 50581623 |
Blood pressure inadequately controlled | 20.06 | 12.56 | 15 | 18628 | 4365 | 50582116 |
Withdrawal syndrome | 19.47 | 12.56 | 28 | 18615 | 17562 | 50568919 |
Pre-existing condition improved | 19.35 | 12.56 | 18 | 18625 | 7079 | 50579402 |
Road traffic accident | 18.97 | 12.56 | 33 | 18610 | 24319 | 50562162 |
Neutropenia | 18.94 | 12.56 | 16 | 18627 | 147949 | 50438532 |
Respiratory arrest | 18.77 | 12.56 | 37 | 18606 | 29972 | 50556509 |
Back disorder | 18.71 | 12.56 | 20 | 18623 | 9285 | 50577196 |
Joint swelling | 18.66 | 12.56 | 39 | 18604 | 245247 | 50341234 |
Fibromyalgia | 18.60 | 12.56 | 47 | 18596 | 44931 | 50541550 |
Lower respiratory tract infection | 18.50 | 12.56 | 6 | 18637 | 95195 | 50491286 |
Back pain | 18.21 | 12.56 | 141 | 18502 | 219889 | 50366592 |
Analgesic drug level increased | 18.17 | 12.56 | 10 | 18633 | 1721 | 50584760 |
Multiple sclerosis relapse | 17.87 | 12.56 | 45 | 18598 | 42919 | 50543562 |
Hypertension | 17.84 | 12.56 | 136 | 18507 | 211067 | 50375414 |
Suspected suicide | 17.40 | 12.56 | 15 | 18628 | 5342 | 50581139 |
Exposure during pregnancy | 16.86 | 12.56 | 12 | 18631 | 121003 | 50465478 |
Wound | 16.81 | 12.56 | 9 | 18634 | 105785 | 50480696 |
Cardiac failure | 16.24 | 12.56 | 4 | 18639 | 76036 | 50510445 |
Alopecia | 16.20 | 12.56 | 42 | 18601 | 245005 | 50341476 |
Febrile neutropenia | 15.97 | 12.56 | 8 | 18635 | 97659 | 50488822 |
Thyroiditis chronic | 15.90 | 12.56 | 3 | 18640 | 12 | 50586469 |
Loss of consciousness | 15.67 | 12.56 | 78 | 18565 | 104275 | 50482206 |
Product dose omission issue | 15.31 | 12.56 | 118 | 18525 | 183720 | 50402761 |
Therapy interrupted | 15.29 | 12.56 | 27 | 18616 | 20125 | 50566356 |
Attention deficit hyperactivity disorder | 15.03 | 12.56 | 10 | 18633 | 2419 | 50584062 |
Therapy cessation | 14.99 | 12.56 | 31 | 18612 | 25980 | 50560501 |
Oesophagitis | 14.37 | 12.56 | 21 | 18622 | 13362 | 50573119 |
Memory impairment | 13.87 | 12.56 | 62 | 18581 | 79298 | 50507183 |
Somnolence | 13.76 | 12.56 | 101 | 18542 | 154884 | 50431597 |
Synovial cyst | 13.75 | 12.56 | 16 | 18627 | 8150 | 50578331 |
Neck pain | 13.51 | 12.56 | 49 | 18594 | 57018 | 50529463 |
Cardio-respiratory arrest | 13.38 | 12.56 | 47 | 18596 | 53845 | 50532636 |
Pharyngeal swelling | 13.26 | 12.56 | 12 | 18631 | 4554 | 50581927 |
Malignant neoplasm of spinal cord | 13.04 | 12.56 | 3 | 18640 | 36 | 50586445 |
Feeling abnormal | 13.04 | 12.56 | 85 | 18558 | 125407 | 50461074 |
Psoriasis | 12.89 | 12.56 | 55 | 18588 | 68945 | 50517536 |
Illness | 12.70 | 12.56 | 28 | 18615 | 24512 | 50561969 |
Suicidal ideation | 12.64 | 12.56 | 47 | 18596 | 55338 | 50531143 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug dependence | 85.31 | 14.87 | 59 | 7894 | 20922 | 29545652 |
Product prescribing error | 55.90 | 14.87 | 43 | 7910 | 17933 | 29548641 |
Respiratory depression | 52.54 | 14.87 | 37 | 7916 | 13486 | 29553088 |
Victim of child abuse | 39.85 | 14.87 | 13 | 7940 | 832 | 29565742 |
Child abuse | 35.85 | 14.87 | 9 | 7944 | 222 | 29566352 |
Depression | 30.15 | 14.87 | 69 | 7884 | 85078 | 29481496 |
Phonophobia | 28.03 | 14.87 | 7 | 7946 | 169 | 29566405 |
Back disorder | 22.40 | 14.87 | 16 | 7937 | 5957 | 29560617 |
Epidural lipomatosis | 22.07 | 14.87 | 8 | 7945 | 703 | 29565871 |
Memory impairment | 20.67 | 14.87 | 36 | 7917 | 36434 | 29530140 |
Intentional product misuse | 19.36 | 14.87 | 34 | 7919 | 34627 | 29531947 |
Anxiety | 18.79 | 14.87 | 58 | 7895 | 85307 | 29481267 |
Serum procollagen type III N-terminal propeptide increased | 18.14 | 14.87 | 4 | 7949 | 55 | 29566519 |
Spinal operation | 18.00 | 14.87 | 10 | 7943 | 2404 | 29564170 |
Back pain | 17.64 | 14.87 | 64 | 7889 | 102220 | 29464354 |
Juvenile idiopathic arthritis | 16.86 | 14.87 | 8 | 7945 | 1386 | 29565188 |
Post-traumatic neck syndrome | 15.77 | 14.87 | 4 | 7949 | 103 | 29566471 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Completed suicide | 65.68 | 12.42 | 189 | 20514 | 224225 | 64253804 |
Necrosis ischaemic | 63.31 | 12.42 | 20 | 20683 | 963 | 64477066 |
Drug dependence | 57.73 | 12.42 | 62 | 20641 | 33250 | 64444779 |
Beta haemolytic streptococcal infection | 50.49 | 12.42 | 20 | 20683 | 1874 | 64476155 |
Pneumonia streptococcal | 46.09 | 12.42 | 20 | 20683 | 2358 | 64475671 |
Gallbladder polyp | 40.44 | 12.42 | 14 | 20689 | 898 | 64477131 |
Acquired haemophilia | 39.35 | 12.42 | 16 | 20687 | 1604 | 64476425 |
Victim of child abuse | 37.20 | 12.42 | 13 | 20690 | 858 | 64477171 |
Anxiety | 36.44 | 12.42 | 145 | 20558 | 202504 | 64275525 |
Product prescribing error | 35.63 | 12.42 | 50 | 20653 | 35219 | 64442810 |
Depression | 35.27 | 12.42 | 134 | 20569 | 183157 | 64294872 |
Child abuse | 34.70 | 12.42 | 9 | 20694 | 211 | 64477818 |
Respiratory depression | 31.08 | 12.42 | 38 | 20665 | 23405 | 64454624 |
Back disorder | 29.56 | 12.42 | 25 | 20678 | 9965 | 64468064 |
Respiratory arrest | 28.98 | 12.42 | 57 | 20646 | 52928 | 64425101 |
Spinal operation | 28.35 | 12.42 | 20 | 20683 | 6113 | 64471916 |
Multiple drug therapy | 28.21 | 12.42 | 14 | 20689 | 2240 | 64475789 |
Neutropenia | 27.45 | 12.42 | 22 | 20681 | 239602 | 64238427 |
Exposure via skin contact | 27.12 | 12.42 | 7 | 20696 | 161 | 64477868 |
Migraine | 26.82 | 12.42 | 61 | 20642 | 62616 | 64415413 |
Drug hypersensitivity | 25.79 | 12.42 | 147 | 20556 | 237668 | 64240361 |
Fall | 24.91 | 12.42 | 223 | 20480 | 416603 | 64061426 |
Drug intolerance | 24.51 | 12.42 | 15 | 20688 | 187977 | 64290052 |
Contraindicated product administered | 24.30 | 12.42 | 3 | 20700 | 107826 | 64370203 |
Back pain | 24.15 | 12.42 | 150 | 20553 | 250021 | 64228008 |
Infusion related reaction | 23.05 | 12.42 | 12 | 20691 | 164455 | 64313574 |
Muscle spasms | 23.03 | 12.42 | 98 | 20605 | 140925 | 64337104 |
Memory impairment | 22.94 | 12.42 | 70 | 20633 | 85612 | 64392417 |
Cardiac failure | 22.90 | 12.42 | 7 | 20696 | 132366 | 64345663 |
Diabetes mellitus inadequate control | 22.69 | 12.42 | 31 | 20672 | 21290 | 64456739 |
Drug abuser | 22.45 | 12.42 | 17 | 20686 | 5791 | 64472238 |
Pancytopenia | 22.35 | 12.42 | 9 | 20694 | 143300 | 64334729 |
Back injury | 22.11 | 12.42 | 19 | 20684 | 7738 | 64470291 |
Thrombocytopenia | 21.58 | 12.42 | 24 | 20679 | 223777 | 64254252 |
Intentional product misuse | 21.20 | 12.42 | 61 | 20642 | 72234 | 64405795 |
Road traffic accident | 20.48 | 12.42 | 36 | 20667 | 30709 | 64447320 |
Surgery | 20.05 | 12.42 | 34 | 20669 | 28179 | 64449850 |
Contusion | 20.02 | 12.42 | 81 | 20622 | 113884 | 64364145 |
Phonophobia | 19.87 | 12.42 | 7 | 20696 | 473 | 64477556 |
Multiple sclerosis relapse | 19.83 | 12.42 | 42 | 20661 | 41093 | 64436936 |
Epidural lipomatosis | 19.06 | 12.42 | 8 | 20695 | 869 | 64477160 |
Intervertebral disc degeneration | 18.59 | 12.42 | 22 | 20681 | 13098 | 64464931 |
Feeling abnormal | 18.19 | 12.42 | 88 | 20615 | 133514 | 64344515 |
Overdose | 18.18 | 12.42 | 100 | 20603 | 159466 | 64318563 |
Pain | 18.00 | 12.42 | 263 | 20440 | 553248 | 63924781 |
Serum procollagen type III N-terminal propeptide increased | 17.93 | 12.42 | 4 | 20699 | 48 | 64477981 |
Loss of consciousness | 17.59 | 12.42 | 94 | 20609 | 148271 | 64329758 |
Amnesia | 17.44 | 12.42 | 44 | 20659 | 48225 | 64429804 |
Treatment failure | 17.16 | 12.42 | 8 | 20695 | 116808 | 64361221 |
Analgesic drug level increased | 16.92 | 12.42 | 10 | 20693 | 2260 | 64475769 |
Hypertension | 16.65 | 12.42 | 141 | 20562 | 259120 | 64218909 |
Intervertebral disc protrusion | 16.61 | 12.42 | 26 | 20677 | 20165 | 64457864 |
Off label use | 16.15 | 12.42 | 128 | 20575 | 632678 | 63845351 |
Suicidal ideation | 15.65 | 12.42 | 52 | 20651 | 66490 | 64411539 |
Emotional distress | 15.33 | 12.42 | 35 | 20668 | 36003 | 64442026 |
Attention deficit hyperactivity disorder | 15.09 | 12.42 | 10 | 20693 | 2760 | 64475269 |
Pain in extremity | 15.03 | 12.42 | 156 | 20547 | 302929 | 64175100 |
Cardio-respiratory arrest | 15.00 | 12.42 | 67 | 20636 | 98326 | 64379703 |
Maternal exposure during pregnancy | 14.98 | 12.42 | 6 | 20697 | 95878 | 64382151 |
Blood pressure inadequately controlled | 14.96 | 12.42 | 13 | 20690 | 5371 | 64472658 |
Malignant neoplasm progression | 14.71 | 12.42 | 9 | 20694 | 112862 | 64365167 |
Insomnia | 14.55 | 12.42 | 111 | 20592 | 197725 | 64280304 |
Oesophageal stenosis | 14.33 | 12.42 | 11 | 20692 | 3823 | 64474206 |
Therapy cessation | 14.32 | 12.42 | 32 | 20671 | 32457 | 64445572 |
Interstitial lung disease | 13.89 | 12.42 | 7 | 20696 | 97725 | 64380304 |
Pyrexia | 13.78 | 12.42 | 114 | 20589 | 558530 | 63919499 |
Systemic lupus erythematosus | 13.61 | 12.42 | 4 | 20699 | 77608 | 64400421 |
Suspected suicide | 13.08 | 12.42 | 15 | 20688 | 8639 | 64469390 |
Intervertebral disc displacement | 13.04 | 12.42 | 5 | 20698 | 429 | 64477600 |
Drug interaction | 12.94 | 12.42 | 66 | 20637 | 362017 | 64116012 |
Therapy interrupted | 12.75 | 12.42 | 23 | 20680 | 20013 | 64458016 |
Pharyngeal swelling | 12.66 | 12.42 | 12 | 20691 | 5547 | 64472482 |
Vision blurred | 12.66 | 12.42 | 60 | 20643 | 90256 | 64387773 |
Spinal osteoarthritis | 12.54 | 12.42 | 19 | 20684 | 14322 | 64463707 |
Febrile neutropenia | 12.42 | 12.42 | 26 | 20677 | 187631 | 64290398 |
None
Source | Code | Description |
---|---|---|
ATC | M03BA03 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Carbamic acid esters |
ATC | M03BA53 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Carbamic acid esters |
ATC | M03BA73 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Carbamic acid esters |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D009125 | Muscle Relaxants, Central |
MeSH PA | D009465 | Neuromuscular Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
CHEBI has role | CHEBI:51371 | muscle relaxants |
FDA PE | N0000175730 | Centrally-mediated Muscle Relaxation |
FDA EPC | N0000175737 | Muscle Relaxant |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Spasticity | indication | 221360009 | |
Muscle Spasm with Pain | indication | ||
Tetanus Adjunct Treatment | indication | ||
Alcoholism | contraindication | 7200002 | |
Peptic ulcer | contraindication | 13200003 | DOID:750 |
Gastrointestinal ulcer | contraindication | 40845000 | |
Vitamin K deficiency | contraindication | 52675005 | DOID:11249 |
Nasal polyp | contraindication | 52756005 | |
Acute nephropathy | contraindication | 58574008 | |
Factor II deficiency | contraindication | 73975000 | |
Reye's syndrome | contraindication | 74351001 | DOID:14525 |
Gastrointestinal hemorrhage | contraindication | 74474003 | |
Thrombotic thrombocytopenic purpura | contraindication | 78129009 | DOID:10772 |
Gout | contraindication | 90560007 | DOID:13189 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Hemophilia | contraindication | 90935002 | |
Anemia due to enzyme deficiency | contraindication | 111577008 | |
von Willebrand disorder | contraindication | 128105004 | DOID:12531 |
Seizure disorder | contraindication | 128613002 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Breastfeeding (mother) | contraindication | 413712001 | |
Acute erosive gastritis | contraindication | 444926003 |
Species | Use | Relation |
---|---|---|
Cats | Acute inflammatory and traumatic conditions of the skeletal muscles | Indication |
Cats | Reducing muscular spasms | Indication |
Dogs | Acute inflammatory and traumatic conditions of the skeletal muscles | Indication |
Dogs | Reducing muscular spasms | Indication |
Horses | Acute inflammatory and traumatic conditions of the skeletal muscles | Indication |
Horses | Reducing muscular spasms | Indication |
Product | Applicant | Ingredients |
---|---|---|
Robaxin-V Injectable | Kinetic Technologies LLC | 1 |
Robaxin-V Tablets | Zoetis Inc. | 1 |
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Carbonic anhydrase 1 | Enzyme | INHIBITOR | Ki | 7.60 | IUPHAR | CHEMBL |
ID | Source |
---|---|
4017879 | VUID |
N0000146232 | NUI |
D00402 | KEGG_DRUG |
4017879 | VANDF |
C0025659 | UMLSCUI |
CHEBI:6832 | CHEBI |
CHEMBL1201117 | ChEMBL_ID |
DB00423 | DRUGBANK_ID |
D008721 | MESH_DESCRIPTOR_UI |
4107 | PUBCHEM_CID |
6829 | IUPHAR_LIGAND_ID |
776 | INN_ID |
125OD7737X | UNII |
6845 | RXNORM |
5075 | MMSL |
988 | MMSL |
d00965 | MMSL |
001669 | NDDF |
387486000 | SNOMEDCT_US |
83973001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-1290 | TABLET | 500 mg | ORAL | ANDA | 21 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-1292 | TABLET | 750 mg | ORAL | ANDA | 21 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9909 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 11 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9909 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 11 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-1740 | TABLET | 500 mg | ORAL | ANDA | 23 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-1825 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 20 sections |
ROBAXIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6103 | INJECTION | 100 mg | INTRAMUSCULAR | NDA | 22 sections |
ROBAXIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6217 | INJECTION | 100 mg | INTRAMUSCULAR | NDA | 22 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7057 | TABLET | 500 mg | ORAL | ANDA | 22 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7057 | TABLET | 500 mg | ORAL | ANDA | 22 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7058 | TABLET | 750 mg | ORAL | ANDA | 22 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7058 | TABLET | 750 mg | ORAL | ANDA | 22 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-664 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 19 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-665 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 19 sections |
Methocarbamol Tablets, USP, 500 mg | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-722 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 20 sections |
Methocarbamol Tablets, USP, 750 mg | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-723 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 20 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-259 | TABLET | 750 mg | ORAL | ANDA | 21 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-464 | TABLET | 750 mg | ORAL | ANDA | 22 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-622 | TABLET | 750 mg | ORAL | ANDA | 19 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-773 | TABLET | 500 mg | ORAL | ANDA | 22 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-956 | TABLET | 750 mg | ORAL | ANDA | 23 sections |
METHOCARBAMOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-147 | TABLET | 500 mg | ORAL | ANDA | 21 sections |
METHOCARBAMOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-148 | TABLET | 750 mg | ORAL | ANDA | 21 sections |
ROBAXIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-981 | TABLET, FILM COATED | 750 mg | ORAL | NDA | 11 sections |
METHOCARBAMOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17511-505 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 20 sections |
METHOCARBAMOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17511-506 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 20 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-078 | TABLET | 500 mg | ORAL | ANDA | 21 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-079 | TABLET | 750 mg | ORAL | ANDA | 21 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-675 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 23 sections |
Methocarbamol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-533 | TABLET | 500 mg | ORAL | ANDA | 19 sections |